Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia
Retention of HUCPVCs in the lungs. (a) Representative image of CFSE-labeled HUCPVCs using fluorescence microscopy (×100 original magnification). (b) Flow cytometry analysis of CFSE-labeled HUCPVCs. (A) Dot plot for the unstained control. (B) Dot plot for CFSE-labeled HUCPVCs showing that more than 99% of the cells were positively stained. Data are representative of three independent experiments. (c) Detection of CFSE-labeled HUCPVCs in the lungs by flow cytometry. CFSE-labeled HUCPVCs ( cells) were administered via the pulmonary artery as described in Materials and Methods (Section 2.2). At the end of the experiment, samples from the upper, middle, and lower sections of the left lung were obtained and analyzed by flow cytometry. Data are representative of three independent experiments. (d) Identification of HUCPVCs in the lungs by immunostaining against human vimentin. Representative images of lung tissue sections obtained at the end of the perfusion from the lungs receiving infusion of vehicle (A) or HUCPVCs (B) at ×400 original magnification (inset: ×1000 original magnification). Black arrows indicate vimentin-positive cells. Please note that vimentin-positive cells show a diffuse cytoplasmic staining.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.